This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Current and Emerging Treatment Options for Lung Cancer and Head & Neck Carcinoma

Current and Emerging Treatment Options for Lung Cancer and Head & Neck Carcinoma

Format

Webcast

Time to Complete

2 hours

Released

December 30, 2019

Expires

December 30, 2020
Add to Queue


Maximum Credits

2.00 / AMA PRA Category 1 CreditTM
2.00 / CNE Contact Hours

Accredited Providers

Jointly provided by Amedco and CancerNet, LLC

Commercial Supporter

Supported by Merck Sharpe & Dohme Corp.

Program Description

This webcast is intended to improve care of patients with lung cancer and head and neck carcinoma by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

This webcast is designed to meet the educational needs of hematologists/oncologists, physician assistants, nurse practitioners, registered nurses, pharmacists and fellows in training involved in the diagnosis and treatment of patients with lung cancer and head and neck carcinoma.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Assess the clinical data supporting the optimal use of anti-PD-1 and PD-L1 antibodies in the treatment of NSCLC
  • Cite the clinical data supporting the optimal use of anti-PD-1, PD-L1 antibodies and combination approaches in the treatment of SCLC
  • Evaluate PD-1/PD-L1 interactions through nivolumab and pembrolizumab that contribute to better outcomes for patients with SCCHN
  • Appraise the mechanisms of action of PD-1 and PD-L1 blockade in SCCHN with high mutational burden and implication of immune response

Disclosure of Conflicts of Interest Policy

It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Faculty

Patrick Forde MB, MRCP
Director
Thoracic Cancer Clinical Research Program
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD

Dr. Forde discloses the following:
Consultant: AstraZeneca, Bristol-Myers Squibb, Janssen
Advisory Board/Steering Committee: AstraZeneca, Bristol-Myers Squibb, Janssen
Research Support: Corvus Pharmaceuticals, Kyowa, Novartis

David E. Gerber, MD
Professor
Departments of Internal Medicine and Population & Data Sciences
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, TX

Dr. Gerber discloses the following:
Research Funding: AstraZeneca, BerGenBio, Karyopharm
Stock Ownership: Gilead
Consultant: Samsung Bioepis

Tanguy Seiwert, MD
Director
Head & Neck Oncology Disease Group
Co-Director
Bloomberg~Kimmel Institute for Immunotherapy - HNC Program
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Dr. Seiwert discloses the following:
Advisory Board: Merck/MSD, AstraZeneca, BMS, Loxo, Innate, Aduro, Bayer, Nanobiotics, Roche Diagnostic, Maverick, Cue, Rakuten
Stock Options: SQZ
Research Funding: Jounce, Merck/MSD, Verseau Trial Funding
Hopkins-BMS Institutional Contract: BMS, AstraZeneca, Nanobiotix, Merck/MSD

Planners And Managers Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE webcast:

Kamatham A. Naidu, PhD (CancerNet, LLC), has no relevant financial relationships.
Brian Waggoner (CancerNet, LLC) has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Credit

2.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation Statement

Amedco designates this enduring material for a maximum of 2.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

2.00

Type

CNE Contact Hour(s)

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation Statement

Amedco approves this enduring material for a maximum of 2.00 contact hours.

Disclosure of Unlabeled Use

It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Instructions

There are no fees for participating and receiving CME credit for this webcast. During the period Dec 30, 2019 through Dec 30, 2020, participants must read all the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 80% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CME/CE Provider at certicate@amedcoemail.com

If you have any other questions relating to your certificate or other issues with this activity, please contact
myCME.Support@haymarketmedical.com.

Copyright

© CancerNET, LLC 2020

Privacy Policy

Amedco observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue